T-cell non-Hodgkin lymphoma is a group disease with unique clinical and pathological features. It is more aggressive and has lower chemotherapy sensitivity than B-cell lymphoma. In recent years, to search for effective treatment, novel agents such as gemcitabine, targeted therapy combined with chemotherapy and high-dose chemotherapy combined with hematopoietic stem cell transplantation are applied in the treatmentof T-cell non-Hodgkin lymphoma. And some progresses are achieved.

Aggressive T cell non-Hodgkin lymphomas are a group of highly malignant tumors characterized by rapid progress and short survival.This is especially true for patients who have a poor response to treatment because of their drug resistance.Hence,to clarify the mechanism of this resistance will have important guiding significance in reversing drug resistance and improving poor prognosis of aggressive T cell nonHodgkin's lymphomas.

Fluorouracil,platinum and taxane are commonly used in the current chemotherapy of gastric cancer.The relationship between the key molecular biomarkers of mechanism of drug action and drug sensitivity has become a researchful hotspot,which is the prerequisite to achieve individualized treatment of gastric cancer.

A variety of molecular markers are related to the prognosis of gastric cancer,such as the the loss expression of AT rich interactive domain 1A (ARID1A),the overexpression of CD133 and survivin are releated to the incidence and poor prognosis of gastric cancer; leptin,CD44 and microRNA (miRNA) are releated to the invasion and metastasis of gastric cancer; the low expression of secreted protein acidic and rich in cysteine (SPARC) contributes to the angiogenesis of gastric cancer,but the relationship between SPARC and prognosis needs further study; the expression and gene polymorphism of excision repair cross-complementing 1 (ERCC1) may be useful for choice of medication in the treatment of gastric cancer.

Peripheral T-cell lymphomas (PTCLs) are insensitive to traditional chemotherapies which lack of effective treatments and have worse prognosis than B-cell lymphomas.Angiogenesis plays an essential role in the malignant tumor growth.Recently,studies have shown that the expression level of VEGF is related to the clinical characteristic and prognosis of PTCL.Novel drugs based on anti-angiogenic theory show curative effect in the preliminary clinical trials for the treatment of PTCL.

Neoplasms of the small intestine have no specific features at early stage,and the prognosis is poor.The 5-year survival rate of all the patients is about 30％ and the middle survival time is 19 months.The retrospective analysis shows that adjuvant chemotherapy after surgical resection might improve the disease free survival while the overall survival is not improved obviously.The patients who are at advanced stage or have regional lymph node metastasis may obtain benefits from adjuvant chemotherapy.Palliative chemotherapy may improve progress free survival and overall survival of patients who are at advanced stage.The therapeutic effect of patients at advanced stage using FOLFOX regimen ( 5-fluorouracil,calcium folinate and oxaliplatin ) is better compared with other regimens.The molecular targeted therapy of small intestine cancer is still in the study process and advanced studies are also needed for chemotherapy.

Objective To investigate the correlation between the expression of CD10,Bcl-6,VEGF with clinical characteristics and the prognosis in the primary gastrointestinal diffuse large B-cell lymphoma. Methods The clini-cal characteristics data of 66 patients with PGI-DLBCL were determined the levels of CD10,Bcl-6 and VEGF by immunohisto-chemical staining. Analyzed their correlation via Kaplan-Meier method and Log-rand test. Results Among those 66 patients,there were 36 cases(54. 5% )of primary stomach,while other 30 cases(45. 5% )were primary intestinal. 39 cases were GCB and 27 cases were non-GCB. The tumor stage and IPI were inverse propor-tion with the prognosis. The median progression-free-survival of GCB was 21. 50 months while non-GCB was 12. 00 months. The positive expression rate of Bcl-6 was 43. 9%(29 / 66)while that of CD10 was 34. 8%(23 / 66)and there were 29 cases(43. 9% )with positive expression of VEGF. Log-rank test revealed there was a positive correc-tion between the positive impression of CD10,Bcl-6 and PFS. On the contrary,the relationship between the ex-pressions of VEGF and PFS was negative. The expressions of CD10,Bcl-6 and VEGF were not correlated with clini-cal features. Cox multivariable analysis showed that the curative effect,the expressions of Bcl-6 and VEGF were in-dependent prognostic factors. Conclusion PGI-DLBCL is a highly invasive and heterogeneous malignancy. The stage of disease,the Hans classification,the level of IPI,the expression of CD10,Bcl-6 and VEGF may play im-portant roles in predicting the curative effect and the prognosis of the disease.

Clinical oncology is becoming more and more important as the tumor incidence increases year by year. According to the need of clinical teaching, some important contents in teaching should be emphasized. And some ideas should be pard attention to such as chronic disease needing long-period and long period of treatment of chronic tumor diseases, necessary pathlolgical diagnosis, in despensible evidence-based medicine, multidisciplinary treatment combined with individualized treatment, caring psychological problems and pain in cancer patients, recognizing tumor research progresses by way of molecular targeted therapy. Finally, some teaching methods to raise study interest in a flexible way were put forward.

Objective To explore the prognostic factor by analyzing clinical characters, pathologic features and treatment methods of thymic carcinoma. Methods From January 2000 to Deceber 2011, 71 patients received re-section of thymic carcinoma. They were analyzed retrospectively based on Masaoka stage(stageII 7,stageIII 33, stageIV 31). The clinical factors included histological classification, Masaoka stage, treatment and prognosis. Sur-vival rate was calculated and the survival curve was plotted by Kaplan-Meimer and Log-Rank method, Multi-analy-sis was carried out by COX regression. Results For these patients, the median survival time was 57. 2 months, the 5-year survival rate was 47. 9%. 25 patients received complete resection with 5-years survival rate 68%, 46 patients received partial resection with 5-years survival rate 36. 9%. 41 patients whose lump size was greater than or equal to 8 cm with 5-years survival rate 53. 6%, 40% with lower than 8 cm. Histology Masaoka staging with 5-years survival rate was stage II(57. 1%) , stage III(69. 7%) and stage IV(29. 0%) , respectively. Defferent his-tological type with 5-years survival rate squamous carcinoma(55. 1%) , adenocarcinoma (14. 3%) ,small cell car-cinoma ( 28. 6%) , adenosquamous carcinoma ( 33. 3%) , and carcinoid ( 100%) , respectively. The operation method, the maximum diameter, mass Masaoka stage and different pathology types for survival were statistically dif-ferent (P<0. 05). Preoperative treatment, postoperative radiotherapy and differentiation degree of survival had no statistical difference. Conclusion Surgical method, lump size, masaoka stage and histological type are the impor-tant factors affecting prognosis. Adjuvant radiotherapy maybe is not the poor prognosis factor of thymic tumors. Sur-gical method and lump size are the significant independent prognostic factors in patients with thymic tumors.

The cytogenotoxic effect of Na_2SeO_3 on lymphocytes in human whole blood culture was studied. This was done by means of analysis of sisterchromatid exchange (SCE) and determination of unscheduled DNA synthesis (UDS) with the use of scintillometric procedure and autoradiographic observation. The experiments showed that Na_2SeO_3induced a significant increase of SCE value and higher levels of UDS. These results indicate that Na_2SeO_3 has DNA-damaging potential and cytogenotocity, its threshold concentration was 6.48?10~(-7)mol/L.